Wed, Mar 25, 2026

India’s Low-Cost Weight-Loss Drugs Could Transform the Global Obesity Treatment Market

EU-India

Sarah J

Posted on Wed, Mar 25, 2026

2 min read

Share the article with your network

India is emerging as a major force in the global healthcare landscape as affordable versions of popular weight-loss drugs begin to reshape access to obesity treatment worldwide.

The shift comes after the patent expiry of semaglutide the key ingredient behind blockbuster drugs like Ozempic and Wegovy allowing Indian pharmaceutical companies to launch significantly cheaper generic alternatives.

These generics are priced far lower than their Western counterparts, in some cases reducing treatment costs by up to 70-80%, making them accessible to a much larger population.

India’s strong pharmaceutical manufacturing ecosystem is enabling the rapid rollout of these drugs, with dozens of companies entering the market and introducing multiple versions in a short period.

This development has the potential to significantly impact global healthcare dynamics. As one of the world’s largest producers of generic medicines, India could expand access to obesity and diabetes treatments across emerging markets, and eventually influence pricing and availability even in developed economies.

However, the rapid expansion also raises concerns around regulation, safe usage, and quality control, as authorities work to ensure that these medicines are prescribed and consumed responsibly.

Positions India as a global leader in affordable healthcare solutions
Opens opportunities for European pharma, biotech, and healthtech collaborations
Highlights the growing importance of generic drug innovation and scalability
Creates new pathways for AI-driven drug discovery, distribution, and patient care
Signals a shift toward accessible, cost-efficient global healthcare models

India’s move into low-cost weight-loss drugs is not just a domestic healthcare story it has the potential to reshape the global pharmaceutical and health innovation landscape, aligning strongly with SEINET’s focus on cross-border impact.

-----

Join SEINET - The EU-UK-India Tech Corridor

The digital partnership infrastructure for tech businesses and leaders across Europe, the UK, and India. Start with a verified community and unlock access to the exclusive Leaders Network for qualified founders and decision-makers.

The Hindu reports that Moving Tech Innovations, the Bengaluru-based company behind Namma Yatri, has acquired Netherlands-based Automicle Holding BV in its first international move, marking a direct push into the European urban mobility market.The deal, announced on March 26, gives Moving Tech a foothold on the continent with a platform that already works with European city authorities on digital parking systems and integrated public transport. Financial terms were not disclosed.The strategic rationale is straightforward: European ride-hailing remains dominated by platforms that charge drivers commissions of anywhere between 10 and 50%. Moving Tech's entire model is built around eliminating that layer. Across its Indian platforms, including Namma Yatri, Yatri Sathi, and Bharat Taxi, the company has completed over 150 million trips and channelled more than Rs 2,500 crore in earnings directly to drivers without taking a cut."When we built Namma Yatri, we put cities and their people first," said co-founders Magizhan Selvan and Shan MS. "These are not local solutions; they are universal principles. Cities everywhere are seeking a mobility model that is open and community-led."Automicle's co-founders framed the deal as a two-way exchange, with European expertise in parking and integrated urban transport flowing back to Indian cities alongside Moving Tech's open-network model heading west.The acquisition follows a pre-Series A extension round in which Namma Yatri raised Rs 39.75 crore, roughly $4.4 million, with participation from Juspay founder Vimal Kumar. The company also pointed to renewed momentum in India-EU Free Trade Agreement talks as broader context for the move.

Tue, Mar 31, 2026